Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2022

01-02-2022 | Care | Original Article

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

Authors: Jee-Fu Huang, Ming-Yen Hsieh, Yu-Ju Wei, Jen-Yu Hung, Hsuan-Ti Huang, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Tyng-Yuan Jang, Po-Yao Hsu, Po-Cheng Liang, Chia-Yen Dai, Zu-Yau Lin, Ming-Lung Yu, Wan-Long Chuang

Published in: Hepatology International | Issue 1/2022

Login to get access

Key points

Question

Is hepatitis C virus (HCV) micro-elimination achievable at the hospital level with the structured strategies?

Findings

The multidirectional program included the HCV reflex test for hospital personnel, outpatient surveillance, a call-back system, and surveillance of cancer patients prior to chemotherapy. Through the plans of the study, 97.8% of the HCV-viremic patients successfully received linkage-to-treat. The results of each strategy sufficiently met the 2030 elimination goal by the World Health Organization (WHO).

Meaning

HCV micro-elimination is achievable at the hospital level based on patient safety, staff occupational safety and infection control.
Literature
1.
Yu ML, Chuang WL. New treatments for HCV: perspective from Asia. Clin Liver Dis (Hoboken). 2015;5(1):17–21CrossRef
2.
Panel A-IHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–92.
3.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218CrossRef
4.
Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10(5):681–701CrossRef
5.
Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int. 2017;37(2):159–172CrossRef
6.
Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020;119(7):1135–1157CrossRef
7.
Huang CF, Wu PF, Yeh ML, Huang CI, Liang PC, Hsu CT, et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clin Mol Hepatol. 2021;27(1):136–143CrossRef
8.
Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010;26(9):461–469CrossRef
9.
Yang TH, Fang YJ, Hsu SJ, Lee JY, Chiu MC, Yu JJ, et al. Microelimination of Chronic Hepatitis C by Universal Screening Plus direct-acting antivirals for incarcerated persons in Taiwan. Open Forum Infect Dis. 2020;7(8):ofaa301CrossRef
10.
Yu ML, Huang CF, Wei YJ, Lin WY, Lin YH, Hsu PY, et al. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut. 2020;70:2349–2358CrossRef
11.
Tsai PC, Huang CI, Yeh ML, Huang CF, Hsieh MH, Yang JF, et al. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. BMJ Open. 2021;11(3):e042861CrossRef
12.
El-Sokkary RH, Tash RME, Meawed TE, El Seifi OS, Mortada EM. Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities. Infect Drug Resist. 2017;10:357–364CrossRef
13.
Forns X, Martinez-Bauer E, Feliu A, Garcia-Retortillo M, Martin M, Gay E, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology. 2005;41(1):115–122CrossRef
14.
15.
Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. Kaohsiung J Med Sci. 2021;37(1):7–11CrossRef
16.
Huang JF, Lu SN, Chue PY, Lee CM, Yu ML, Chuang WL, et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol Infect. 2001;127(3):485–492CrossRef
17.
Tsai PS, Chang CJ, Chen KT, Chang KC, Hung SF, Wang JH, et al. Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int. 2011;31(7):971–979CrossRef
18.
Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol. 1998;51(9):733–738CrossRef
19.
Huang CF, Huang JF, Dai CY, Yu ML, Lu SN, Hsieh MY, et al. Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. Trans R Soc Trop Med Hyg. 2008;102(9):929–934CrossRef
20.
Yu ML, Yeh ML, Tsai PC, Huang CI, Huang JF, Huang CF, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine. 2015;94(13):e690CrossRef
21.
22.
Konerman MA, Thomson M, Gray K, Moore M, Choxi H, Seif E, et al. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. Hepatology. 2017;66(6):1805–1813CrossRef
23.
Lu MY, Chen CT, Shih YL, Tsai PC, Hsieh MH, Huang CF, et al. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Sci Rep. 2021;11(1):8554CrossRef
24.
Gale HB, Dufour DR, Qazi NN, Kan VL. Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation. J Clin Microbiol. 2011;49(8):3036–3039CrossRef
Metadata
Title
Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
Authors
Jee-Fu Huang
Ming-Yen Hsieh
Yu-Ju Wei
Jen-Yu Hung
Hsuan-Ti Huang
Ching-I Huang
Ming-Lun Yeh
Chung-Feng Huang
Tyng-Yuan Jang
Po-Yao Hsu
Po-Cheng Liang
Chia-Yen Dai
Zu-Yau Lin
Ming-Lung Yu
Wan-Long Chuang
Publication date
01-02-2022
Publisher
Springer India
Keywords
Care
Hepatitis C
Published in
Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10275-7

Other articles of this Issue 1/2022

Hepatology International 1/2022 Go to the issue

Guidelines

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

Original Article

Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies

Review Article

Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review

Original Article

Establishment and validation of a prognostic model for hepatitis B virus‑related acute-on-chronic liver failure patients with bacterial infection

Original Article

Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study

Original Article

Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits